In vitro transformation of mesenchymal stem cells induces gradual genomic hypomethylation

Laurence Wild1, Juan M Funes, Chris Boshoff

  • 1CRUK Viral Oncology Group, UCL Cancer Institute, University College London, 72 Huntley Street, WC1E 6BT, UK.

Carcinogenesis
|May 15, 2010
PubMed

Insights

Global DNA hypomethylation in cancer, a poorly understood epigenetic alteration, was investigated in stepwise transformed mesenchymal stem cells (MSCs). Results show hypomethylation occurs gradually and late in transformation, not being a requirement for it.

Area of Science:

  • Epigenetics
  • Cancer Biology
  • Stem Cell Biology

Background:

  • Genome-wide DNA hypomethylation is an early epigenetic hallmark of cancer, but its underlying mechanisms remain unclear.
  • Mesenchymal stem cells (MSCs) are implicated as the origin of sarcomas, making them a relevant model for cancer transformation studies.

Purpose of the Study:

  • To investigate the role and timing of DNA hypomethylation during the stepwise oncogenic transformation of MSCs.
  • To determine if DNA hypomethylation is a prerequisite for cellular transformation in this model system.

Main Methods:

  • Sequential introduction of five oncogenic steps (hTERT, p53/pRb inactivation, c-Myc/H-Ras activation) into primary MSCs.
  • Analysis of DNA methylation status in repetitive elements (satellite-2, LINE-1) at different transformation stages.
  • Utilizing an inducible estrogen receptor-Ras fusion construct to assess transformation in the absence of hypomethylation.

Main Results:

  • Introduction of oncogenic H-Ras led to significant hypomethylation (54% in satellite-2, 30% in LINE-1) late in the transformation process.
  • DNA hypomethylation was observed to occur gradually, manifesting after 4 weeks post-H-Ras introduction.
  • MSCs could be transformed using an inducible Ras construct without detectable DNA hypomethylation, indicating it's not essential for transformation.

Conclusions:

  • DNA hypomethylation occurs late during the stepwise in vitro transformation of MSCs.
  • The process of DNA hypomethylation appears to be gradual.
  • DNA hypomethylation is not a mandatory requirement for cellular transformation in this MSC model.

Related Concept Videos

Chromatin Modification in iPS Cells01:32

Chromatin Modification in iPS Cells

Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012 for this...
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...